Cargando…

A Survey of Therapeutic Drug Monitoring Status in China

To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Tao., Liang, Hongyan, Huang, Qi, Zhou, Boting, Tang, Mimi, Lou, Jiang, Xiang, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013164/
https://www.ncbi.nlm.nih.gov/pubmed/36920501
http://dx.doi.org/10.1097/FTD.0000000000001060
_version_ 1784906762753671168
author Yin, Tao.
Liang, Hongyan
Huang, Qi
Zhou, Boting
Tang, Mimi
Lou, Jiang
Xiang, Dong
author_facet Yin, Tao.
Liang, Hongyan
Huang, Qi
Zhou, Boting
Tang, Mimi
Lou, Jiang
Xiang, Dong
author_sort Yin, Tao.
collection PubMed
description To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clinicians, pharmacists, and clinical laboratory physicians belonging to different levels of public hospitals were involved as subjects/objects. The contents of the survey included TDM implementation in their hospital and information regarding their opinions and suggestions on TDM work. Mann–Whitney test was used to compare the difference between top tertiary hospitals and non–top tertiary hospitals. RESULTS: A total of 475 questionnaires were collected, 383 from top tertiary hospitals (3A hospitals) and 92 from non–top tertiary hospitals (other than 3A hospitals). A total of 240 clinicians, TDM pharmacists, and clinical laboratory physicians were involved, with an effective rate of 50.5%. Top tertiary hospitals were associated with certain advantages, such as the number of TDM testing facilities, annual sample size, number of monitoring varieties, and interpretation rate of monitoring reports, compared with non–top tertiary hospitals. In particular, β-lactamase inhibitor, olanzapine, carbamazepine, and glucocorticoids seemed to be the main projects that clinicians wanted to assess. The drugs for which TDM was commonly performed included vancomycin, valproic acid, carbamazepine, phenytoin sodium, and methotrexate. The most commonly used detection methods include high-performance liquid chromatography, immunization, 2D-LC, and LC-MS. The monitoring concentration range was found to be inconsistent for most of the drugs. Currently, no unified regulation exists for TDM charges in China, which is no more than ¥200 in general. Clinicians rely on pharmacists for professional guidance. Importantly, improvement in the interpretation of monitoring reports, proficiency testing, and cooperation with clinical departments may aid in improving the level of TDM service. CONCLUSIONS: This survey objectively reflected the current status of TDM work in hospitals in China, and provided a strong reference base for devising strategies for improvement and effective execution of TDM work.
format Online
Article
Text
id pubmed-10013164
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-100131642023-03-15 A Survey of Therapeutic Drug Monitoring Status in China Yin, Tao. Liang, Hongyan Huang, Qi Zhou, Boting Tang, Mimi Lou, Jiang Xiang, Dong Ther Drug Monit Review Article To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clinicians, pharmacists, and clinical laboratory physicians belonging to different levels of public hospitals were involved as subjects/objects. The contents of the survey included TDM implementation in their hospital and information regarding their opinions and suggestions on TDM work. Mann–Whitney test was used to compare the difference between top tertiary hospitals and non–top tertiary hospitals. RESULTS: A total of 475 questionnaires were collected, 383 from top tertiary hospitals (3A hospitals) and 92 from non–top tertiary hospitals (other than 3A hospitals). A total of 240 clinicians, TDM pharmacists, and clinical laboratory physicians were involved, with an effective rate of 50.5%. Top tertiary hospitals were associated with certain advantages, such as the number of TDM testing facilities, annual sample size, number of monitoring varieties, and interpretation rate of monitoring reports, compared with non–top tertiary hospitals. In particular, β-lactamase inhibitor, olanzapine, carbamazepine, and glucocorticoids seemed to be the main projects that clinicians wanted to assess. The drugs for which TDM was commonly performed included vancomycin, valproic acid, carbamazepine, phenytoin sodium, and methotrexate. The most commonly used detection methods include high-performance liquid chromatography, immunization, 2D-LC, and LC-MS. The monitoring concentration range was found to be inconsistent for most of the drugs. Currently, no unified regulation exists for TDM charges in China, which is no more than ¥200 in general. Clinicians rely on pharmacists for professional guidance. Importantly, improvement in the interpretation of monitoring reports, proficiency testing, and cooperation with clinical departments may aid in improving the level of TDM service. CONCLUSIONS: This survey objectively reflected the current status of TDM work in hospitals in China, and provided a strong reference base for devising strategies for improvement and effective execution of TDM work. Therapeutic Drug Monitoring 2023-04 2023-03-01 /pmc/articles/PMC10013164/ /pubmed/36920501 http://dx.doi.org/10.1097/FTD.0000000000001060 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review Article
Yin, Tao.
Liang, Hongyan
Huang, Qi
Zhou, Boting
Tang, Mimi
Lou, Jiang
Xiang, Dong
A Survey of Therapeutic Drug Monitoring Status in China
title A Survey of Therapeutic Drug Monitoring Status in China
title_full A Survey of Therapeutic Drug Monitoring Status in China
title_fullStr A Survey of Therapeutic Drug Monitoring Status in China
title_full_unstemmed A Survey of Therapeutic Drug Monitoring Status in China
title_short A Survey of Therapeutic Drug Monitoring Status in China
title_sort survey of therapeutic drug monitoring status in china
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013164/
https://www.ncbi.nlm.nih.gov/pubmed/36920501
http://dx.doi.org/10.1097/FTD.0000000000001060
work_keys_str_mv AT yintao asurveyoftherapeuticdrugmonitoringstatusinchina
AT lianghongyan asurveyoftherapeuticdrugmonitoringstatusinchina
AT huangqi asurveyoftherapeuticdrugmonitoringstatusinchina
AT zhouboting asurveyoftherapeuticdrugmonitoringstatusinchina
AT tangmimi asurveyoftherapeuticdrugmonitoringstatusinchina
AT loujiang asurveyoftherapeuticdrugmonitoringstatusinchina
AT xiangdong asurveyoftherapeuticdrugmonitoringstatusinchina
AT yintao surveyoftherapeuticdrugmonitoringstatusinchina
AT lianghongyan surveyoftherapeuticdrugmonitoringstatusinchina
AT huangqi surveyoftherapeuticdrugmonitoringstatusinchina
AT zhouboting surveyoftherapeuticdrugmonitoringstatusinchina
AT tangmimi surveyoftherapeuticdrugmonitoringstatusinchina
AT loujiang surveyoftherapeuticdrugmonitoringstatusinchina
AT xiangdong surveyoftherapeuticdrugmonitoringstatusinchina